Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Colorcon
Harvard Business School
Mallinckrodt
Dow
Medtronic

Last Updated: October 16, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Ibalizumab

See Plans and Pricing

« Back to Dashboard

Development status for investigational drug Ibalizumab: Sponsors, patents, clinical trial progress

Ibalizumab is an investigational drug.

There have been 6 clinical trials for Ibalizumab. The most recent clinical trial was a Phase 2 trial, which was initiated on May 15th 2019.

The most common disease conditions in clinical trials are HIV Infections, Immunologic Deficiency Syndromes, and Acquired Immunodeficiency Syndrome. The leading clinical trial sponsors are TaiMed Biologics Inc., Westat, and University of Colorado, Denver.

There are thirteen US patents protecting this investigational drug and fifty-seven international patents.

Recent Clinical Trials for Ibalizumab
TitleSponsorPhase
Study of the Safety of Trogarzo™ Administered as an Undiluted "IV Push"WestatPhase 3
Study of the Safety of Trogarzo™ Administered as an Undiluted "IV Push"TaiMed Biologics Inc.Phase 3
Ibalizumab Plus Optimized Background Regimen in Treatment-Experienced Patients With Multi-Drug Resistant HIV-1WestatPhase 3

See all Ibalizumab clinical trials

Clinical Trial Summary for Ibalizumab

Top disease conditions for Ibalizumab
Top clinical trial sponsors for Ibalizumab

See all Ibalizumab clinical trials

US Patents for Ibalizumab

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Ibalizumab   See Pricing Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein CureVac AG (Tubingen, DE)   See Pricing
Ibalizumab   See Pricing Disulfur bridge linkers for conjugation of a cell-binding molecule HANGZHOU DAC BIOTECH CO., LTD. (Hangzhou, CN)   See Pricing
Ibalizumab   See Pricing Bispecific HIV-1-neutralizing antibodies AARON DIAMOND AIDS RESEARCH CENTER (New York, NY)   See Pricing
Ibalizumab   See Pricing Disulfur bridge linkers for conjugation of a cell-binding molecule HANGZHOU DAC BIOTECH CO., LTD. (Hangzhou, CN)   See Pricing
Ibalizumab   See Pricing Cholestosome vesicles for incorporation of molecules into chylomicrons THERASYN SENSORS, INC. (Eggertsville, NY)   See Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Ibalizumab

Drugname Country Document Number Estimated Expiration Related US Patent
Ibalizumab Australia 2013220749 2032-02-15   See Pricing
Ibalizumab Brazil 112014019627 2032-02-15   See Pricing
Ibalizumab Canada 2862476 2032-02-15   See Pricing
Ibalizumab China 104114705 2032-02-15   See Pricing
Ibalizumab China 108570468 2032-02-15   See Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Mallinckrodt
AstraZeneca
Express Scripts
Johnson and Johnson
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.